3 million people in the US alone currently suffer with Opioid Use Disorder

The economic burden in U.S. of prescription opioid misuse alone is estimated at $78.5 billion annually

• Naltrexone has proven benefits in the prevention of relapse to opioid use, however a deep intramuscular monthly injection into the buttocks is the only formulation currently licensed for this indication.
• A transdermal patch is perfectly suited to deliver sustained drug levels, providing users with round-the-clock opioid receptor antagonism to support their continued abstinence without the need for a clinician administered injection.
• In recognition of the high-potential of a novel transdermal medicine to help tackle the expanding opioid crisis, in 2022 the US government backed National Institute of Drug Abuse (NIDA) awarded Libero the largest NIDA grant issued to an ex-US entity that year to develop its lead medicine.

237 million men and 47 million women worldwide suffer from AUD

Naltrexone in oral form is the most widely used medicine in AUD, however only 2.2% of AUD sufferers in the U.S. receive medication-assisted treatment

Excessive alcohol use costs the U.S. economy $249 billion annually

• Oral Naltrexone is subject to significant first-pass metabolism and due to high levels of the primary metabolite β-Naltrexol, side-effects limit use in some
• Dose-optimised transdermal naltrexone enables sufficient blood levels of Naltrexone to be sustained throughout day and night without the peaks and troughs and metabolism-driven variability of daily oral naltrexone.
• Transdermal naltrexone also offers a lifestyle alternative to people committed to reducing their alcohol intake but not wanting to take a daily tablet